Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®
August 16 2024 - 6:00AM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and
globally integrated biopharmaceutical company is pleased to
announce the funding of a new research agreement for the Naval
Medical Research Command (NMRC), and Walter Reed Army Institute of
Research (WRAIR) Silver Spring, MD, USA.
The focus of this new research agreement is to
develop an enhanced formulation of Travelan potentially expanding
the coverage of the product as a therapeutic measure against
endemic military relevant diarrheal pathogens. This work will
utilize the extensive experience of the US Department of Defense
human infectious disease vaccine programs and will target key
protective antigens of the major enteric bacterial pathogens
Campylobacter, Shigella and Entertoxigenic E. coli strains not
present in the current product formulation.
Immuron will now negotiate a sub award for
collaboration with NMRC and WRAIR to advance this research.
The U.S Department of Defense has recognized the
benefits of Immuron’s technology platform and has an established
long-standing relationship with Immuron to evaluate the commercial
over-the-counter bovine colostrum product Travelan for its
specificity and effectiveness against diarrheal pathogens. As an
extension of the current Shigella (WRAIR), ETEC and Campylobacter
(NMRC) research programs the goal of this award is to identify and
define pathways to formulate, characterize and perform pre-clinical
testing of a military-relevant combined colostrum product.
Infectious diarrhea is the most common illness
reported by travelers visiting developing countries and among US
troops deployed overseas as indicated by the 2019 Department of
Defense (DoD) Infectious Disease Threats Prioritization Panel. The
morbidity and associated discomfort stemming from diarrhea
decreases daily performance, affects judgment, decreases morale and
declines operational readiness. The first line of treatment for
infectious diarrhea is the prescription of antibiotics.
Unfortunately, in the last decade, several enteric pathogens have
demonstrated increasing resistance to commonly prescribed
antibiotics. In addition, traveler’s diarrhea is now recognized by
the medical community to result in post-infectious sequelae,
including post-infectious irritable bowel syndrome (IBS) and
several post-infectious autoimmune diseases. A preventative
treatment that defends against infectious enteric diseases is a
high priority objective for the US Military.
This release has been authorised by the
directors of Immuron Limited.
COMPANY
CONTACT:Steven LydeamoreChief Executive
OfficerPh: +61 (0)3 9824
5254info@immuron.com |
|
|
|
|
|
About Travelan®
Travelan® is an orally administered passive
immunotherapy that prophylactically reduces the likelihood of
contracting travelers’ diarrhea, a digestive tract disorder that is
commonly caused by pathogenic bacteria and the toxins they produce.
Travelan® is a highly purified tabletised preparation of hyper
immune bovine antibodies and other factors, which when taken with
meals bind to diarrhea-causing bacteria and prevent colonization
and the pathology associated with travelers’ diarrhea. In
Australia, Travelan® is a listed medicine on the Australian
Register for Therapeutic Goods (AUST L 106709) and is indicated to
reduce the risk of Travelers’ Diarrhea, reduce the risk of minor
gastro-intestinal disorders and is antimicrobial. In Canada,
Travelan® is a licensed natural health product (NPN 80046016) and
is indicated to reduce the risk of Travelers’ Diarrhea. In the
U.S., Travelan® is sold as a dietary supplement for digestive tract
protection.
About Travelers’ diarrhea
Travelers’ diarrhea is a gastrointestinal
infection with symptoms that include loose, watery (and
occasionally bloody) stools, abdominal cramping, bloating, and
fever, Enteropathogenic bacteria are responsible for most cases,
with enterotoxigenic Escherichia coli (ETEC) playing a dominant
causative role. Campylobacter spp. are also responsible for a
significant proportion of cases. The more serious infections with
Salmonella spp. the bacillary dysentery organisms belonging to
Shigella spp. and Vibrio spp. (the causative agent of cholera) are
often confused with travelers’ diarrhea as they may be contracted
while travelling and initial symptoms are often
indistinguishable.
About ImmuronImmuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory
mediated and infectious diseases.
For more information visit:
http://www.immuron.com
FORWARD-LOOKING STATEMENTS:
This press release may contain “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended. Such statements include, but are not limited to,
any statements relating to our growth strategy and product
development programs and any other statements that are not
historical facts. Forward-looking statements are based on
management’s current expectations and are subject to risks and
uncertainties that could negatively affect our business, operating
results, financial condition and stock value. Factors that could
cause actual results to differ materially from those currently
anticipated include: risks relating to our growth strategy; our
ability to obtain, perform under and maintain financing and
strategic agreements and relationships; risks relating to the
results of research and development activities; risks relating to
the timing of starting and completing clinical trials;
uncertainties relating to preclinical and clinical testing; our
dependence on third-party suppliers; our ability to attract,
integrate and retain key personnel; the early stage of products
under development; our need for substantial additional funds;
government regulation; patent and intellectual property matters;
competition; as well as other risks described in our SEC filings.
We expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in our expectations or any
changes in events, conditions or circumstances on which any such
statement is based, except as required by law.
AcknowledgmentThis work was supported by the
U.S. Army Medical Research and Development Command (USAMRDC),
through the Joint Warfighter Medical Research Program (JWMRP) under
Award Number JW230174 funded for a total of $2,298,359. Opinions,
interpretations, conclusions, and recommendations are those of the
author and are not necessarily endorsed by the Department of
Defense. In conducting research using animals, the investigator(s)
adhered to the laws of the United States and regulations of the
Department of Agriculture. In the conduct of research involving
hazardous organisms or toxins, the investigator(s) adhered to the
CDC-NIH Guide for Biosafety in Microbiological and Biomedical
Laboratories.
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Aug 2023 to Aug 2024